In vivo vasodilatory action of atrial natriuretic peptides in canine coronary circulation

Japanese Circulation Journal

Volumn 60, Issue 5, 1996, Pages 300-310

  Liu, Quan ^a   Nakae, Ichiro ^a   Tsutamoto, Takayoshi ^a   Takaoka, Atsushi ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Atrial natriuretic peptide; Coronary circulation; Dog; HS 142 1

Indexed keywords

ATRIAL NATRIURETIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY VASCULAR RESISTANCE; DRUG EFFECT; HEART OUTPUT; IN VIVO STUDY; NONHUMAN; SECOND MESSENGER; VASODILATATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CORONARY CIRCULATION; CYCLIC GMP; DOGS; FEMALE; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; MALE; NOREPINEPHRINE; POLYSACCHARIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; VASODILATION;

EID: 0029937363     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.60.300     Document Type: Article

References (35)

1. Chu A, Murray JJ, Lin CC, Russel M, Hagen PO, Cobb FR: Preferential proximal coronary dilatation by activators of guanylate cyclase in awake dogs. Am J Physiol 1990; 259: H340-345
2. Chu A, Cobb FR: Effects of atrial natriuretic peptide on proximal epicardial coronary arteries and coronary blood flow in conscious dogs. Circ Res 1987; 61: 485-491
3. Adachi H, Tomoike H, Nishijima H, Egashira S, Nakamura M: Sustained dilatation of large coronary artery by α -human atrial natriuretic peptide in conscious dogs: a comparison with nitroglycerin. Eur J Pharmacol 1989; 161: 189-196
4. Macho P, Vatner SF: Effects of nitroglycerin and nitroprusside on large and small coronary vessels in conscious dogs. Circulation 1981; 64: 1101-1107
5. Lewis BS, Makhoul N, Dakak N, Flugelman MY, Yechiely H, Halon DA, Kahana L: Atrial natriuretic peptide in severe heart failure: Response to controlled changes in atrial pressures during intravenous nitroglycerin therapy. Am Heart J 1992; 124: 1009-1016
6. Tsutamoto T, Bito K, Kinoshita M: Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J 1989; 117: 599-606
7. Morishita Y, Sano T, Ando K, Saitoh Y, Kase H, Yamada K, Matsuda Y: Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 1991; 176: 949-957
8. Tanaka T, Ichimura M, Nakajo S, Snajdar RM, Moroshita Y, Sano T, Yamada K, Inagami T, Matsuda Y: HS-142-1, a novel non-peptide antagonist for atrial natriuretic peptide receptor, selectively inhibits particulate guanylyl cyclase and lowers cyclic GMP in LLC-PK1. Biosci Biotech Biochem 1992; 56: 1041-1045
9. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M: Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994; 89: 2232-2240
10. Goodman CA, Castellana FS: A digital sonomicrometer for two-point length and velocity measurements. Am J Physiol 1982; 243: H634-639
11. Nakae I, Liu Q, Hashimoto K, Sugimoto Y, Tsutamoto T, Kinoshita M: Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 1994; 8: 137-145
12. Luft FC, Lang RE, Aronoff GR, Ruskoaho H, Toth M, Ganten D, Sterzel RB, Unger T: Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats. J Pharmacol Exp Ther 1986; 236: 416-418
13. Katsube N, Schwartz D, Needleman P: Atriopeptin turnover: quantitative relationship between in vivo changes in plasma levels and atrial content. J Pharmacol Exp Ther 1986; 239: 474-479
14. Espiner EA, Crozier IG, Nicholls MG, Cuneo R, Yandle TG, Ikram H: Cardiac secretion of atrial natriuretic peptide. Lancet 1985; 2: 398-399
15. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH: Metabolic clearance rate and plasma half-life of alpha-human atrial natriuretic peptide in man. Life Sci 1986; 38: 1827-1833
16. Tsutamoto T, Kanamori T, Wada A, Kinoshita M: Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 1992; 20: 541-546
17. Honma M, Satoh T, Takezawa J, Ui M: An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small samples from blood and tissue. Biochem Med Metab Biol 1977; 18: 257-273
18. Altman JD, Kinn J, Duncker DJ, Bache RJ: Effect of inhibition of nitric oxide formation on coronary blood flow during exercise in the dog. Cardiovasc Res 1994; 28: 119-124
19. Laxson DD, Dai XZ, Schwartz JS, Bache RJ: Effects of atrial natriuretic peptide on coronary vascular resistance in the intact awake dog. J Am Coll Cardiol 1988; 11: 624-629
20. Herrmann HC, Palacios IF, Dec GW, Scheer JM, Fifer MA: Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure. Am Heart J 1988; 115: 1232-1238
21. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, Burnett JC: Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 1989; 80: 651-657
22. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M: Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993; 87: 70-75
23. Hashimoto K, Kinoshita M, Ohbayashi Y: Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs. Cardiovasc Drug Ther 1991; 5: 131-138
24. Adachi H, Tomoike H, Nishijima H, Hayashi Y, Yamada A, Nakamura M: Effects of verapamil and nitroglycerin on coronary and systemic hemodynamics in conscious dogs. J Pharmacol Exp Ther 1987; 241: 1072-1078
25. Imagawa J, Akima M, Nabata H, Taira N: Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide. J Cardiovasc Pharmacol 1992; 19: 108-114
26. Bache RJ, Dai XZ, Schwartz JS, Chen DG: Effects of atrial natriuretic peptide in the canine coronary circulation. Circ Res 1988; 62: 178-183
27. Canty JM Jr, Schwartz JS: Nitric oxide mediates flow-dependent epicardial coronary vasodilatation to changes in pulse frequency but not mean flow in conscious dogs. Circulation 1994; 89: 375-384
28. Kleinert HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh JH: Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium- induced vascular contractility. Hypertension 1984; 6: 1143-147
29. O'Murchu B, Miller VM, Perrella MA, Burnett JC Jr: Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest 1994; 93: 165-171
30. Ishizaka H, Okumura K, Yamabe H, Tsuchiya T, Yasue H: Endothelium-derived nitric oxide as a mediator of acetylcholine-induced coronary vasodilation in dogs. J Cardiovasc Pharmacol 1991; 18: 665-669
31. Thomassen AR, Bagger JP, Nielsen TT, Pedersen EB: Atrial natriuretic peptide during pacing in controls and patients with coronary arterial disease. Int J Cardiol 1987; 17: 267-276
32. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F, Rapoport RM: Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA 1984; 81: 7661-7664
33. Moe GW, Canepa-Anson R, Armstrong PW: Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. J Cardiovasc Pharmacol 1992; 19: 691-700
34. Riegger GAJ, Elsner D, Kromer EP, Daffner C, Forssmann WG, Muders F, Pascher EW, Kochsiek K: Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation 1988; 77: 398-406
35. Wambach G, Schittenhelm U, Bonner G, Kaufmann W: Renal and adrenal resistance against atrial natriuretic peptide in congestive heart failure: effect of angiotensin I-converting enzyme inhibition. Cardiology 1989; 76: 418-427